Form 4: Terns Pharmaceuticals Director Hongbo Lu Acquires Stock Options
SEC Form 4
Director Hongbo Lu acquired stock options for 32,000 shares of Terns Pharmaceuticals common stock on June 10, 2024.
Summary
- Hongbo Lu, a director of Terns Pharmaceuticals, acquired stock options on June 10, 2024.
- The options grant the right to buy 32,000 shares of Terns Pharmaceuticals common stock at an exercise price of $6.99.
- The options vest in full on the earlier of the first anniversary of the grant date or immediately prior to the next Annual Meeting following the grant date.
- The options expire on June 9, 2034.
Sentiment
Score: 5
Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is neither particularly positive nor negative.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It is common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of stock option grant and transaction. |
| 06/10/2025 | First possible vesting date of the stock options (one year after grant). |
| 06/09/2034 | Expiration date of the stock options. |
| 06/14/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.